Logo for GNW.png
BioLizard Welcomes Arjan van Manen as Commercial Director and Announces Presence at JPM Week in San Francisco
January 09, 2025 09:00 ET | BioLizard nv
Arjan van Manen joins BioLizard as Commercial Director, bringing over 20 years of commercial leadership experience in life sciencesMeet BioLizard’s Arjan van Manen and CEO Liesbeth Ceelen at Biotech...
quantro_logo_for GNW.png
QUANTRO Therapeutics achieves breakthrough in transcriptomic drug discovery with first successful simultaneous 10-target multiplex-screening
January 07, 2025 08:30 ET | QUANTRO Therapeutics GmbH
QUANTRO’s proprietary time-resolved functional transcriptomic discovery platform accelerates target screening for complex indications in oncology and inflammationQUANTRO CEO Dr. Michael Bauer to...
Logo Syntekabio.png
Syntekabio to Showcase AI-Driven Drug Discovery Solutions at Biotech Showcase 2025
December 20, 2024 13:15 ET | Syntekabio USA Inc.
NEW YORK, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Syntekabio (KOSDAQ: 226330), a leading artificial intelligence (AI)-driven drug development company, is pleased to announce its participation in Biotech...
plus_logo.png
Plus Therapeutics Showcases Leptomeningeal Metastases Programs at the 2024 SNO Annual Meeting in Houston, Texas
October 29, 2024 07:30 ET | Plus Therapeutics Inc.
Plus Therapeutics Showcases Leptomeningeal Metastases Programs at the 2024 SNO Annual Meeting in Houston, Texas
plus_logo.png
Plus Therapeutics Reports ReSPECT-GBM Clinical Trial Update at the 2024 Congress of Neurological Surgeons Annual Meeting
October 01, 2024 07:30 ET | Plus Therapeutics Inc.
Plus Therapeutics Reports ReSPECT-GBM Clinical Trial Update at the 2024 Congress of Neurological Surgeons Annual Meeting
plus_logo.png
Plus Therapeutics Showcases New Interim ReSPECT-GBM Phase 2 Trial Data at the 2024 Congress of Neurological Surgeons Annual Meeting
September 18, 2024 07:30 ET | Plus Therapeutics Inc.
Plus Therapeutics Showcases New Interim ReSPECT-GBM Phase 2 Trial Data at the 2024 Congress of Neurological Surgeons Annual Meeting
plus_logo.png
Plus Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
September 04, 2024 07:30 ET | Plus Therapeutics Inc.
Plus Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Correction: Crossjec
Correction: Crossject présentera au Biotech Showcase le 9 janvier à 16 h30 (Horaire de San Francisco)
January 09, 2024 13:58 ET | CROSSJECT
  Communiqué de presse Crossject présentera au Biotech Showcase le 9 janvier à 16 h30 (Horaire de San Francisco) Dijon, France 09 janvier, 2024 -- Crossject (ISIN : FR0011716265 ; Euronext : ALCJ),...
Full Logo - OKYO .jpg
OKYO Pharma to Present at the Biotech Showcase Conference in San Francisco, January 8-10, 2024
January 05, 2024 09:30 ET | OKYO Pharma LTD
OKYO Pharma to Present at the Biotech Showcase Conference in San Francisco, January 8-10, 2024
AXIAL Logo 2021MAR05.png
Axial Therapeutics to Present at Upcoming Conferences
January 05, 2024 08:05 ET | Axial Therapeutics
WOBURN, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Axial Therapeutics, a clinical-stage biotechnology company dedicated to the development of gut-targeted, small molecule therapeutics for neurological...